Loading…
Influence of lipid-lowering therapy on the progression of coronary artery calcification: A prospective evaluation
Coronary calcification measured by fast computed tomography techniques is a surrogate marker of coronary atherosclerotic plaque burden. In a cohort study, we prospectively investigated whether lipid-lowering therapy with a cholesterol synthesis enzyme inhibitor reduces the progression of coronary ca...
Saved in:
| Published in: | Circulation (New York, N.Y.) N.Y.), 2002-08, Vol.106 (9), p.1077-1082 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c357t-c29e70119e8def9e7d13f8d793ebbd970ab490ccb4f7db14e9b81be75f289d803 |
| container_end_page | 1082 |
| container_issue | 9 |
| container_start_page | 1077 |
| container_title | Circulation (New York, N.Y.) |
| container_volume | 106 |
| creator | ACHENBACH, Stephan ROPERS, Dieter BICKEL, Andrea HABERL, Ralph STEINBECK, Gerhard MOSHAGE, Werner DANIEL, Werner G POHLE, Karsten LEBER, Alexander THILO, Christian KNEZ, Andreas MENENDEZ, Theresa MAEFFERT, Ralph KUSUS, Magda REGENFUS, Matthias |
| description | Coronary calcification measured by fast computed tomography techniques is a surrogate marker of coronary atherosclerotic plaque burden. In a cohort study, we prospectively investigated whether lipid-lowering therapy with a cholesterol synthesis enzyme inhibitor reduces the progression of coronary calcification.
In 66 patients with coronary calcifications in electron beam tomography (EBT), LDL cholesterol >130 mg/dL, and no lipid-lowering treatment, the EBT scan was repeated after a mean interval of 14 months and treatment with cerivastatin was initiated (0.3 mg/d). After 12 months of treatment, a third EBT scan was performed. Coronary calcifications were quantified using a volumetric score. Cerivastatin therapy lowered the mean LDL cholesterol level from 164+/-30 to 107+/-21 mg/dL. The median calcified volume was 155 mm3 (range, 15 to 1849) at baseline, 201 mm3 (19 to 2486) after 14 months without treatment, and 203 mm3 (15 to 2569) after 12 months of cerivastatin treatment. The median annualized absolute increase in coronary calcium was 25 mm3 during the untreated versus 11 mm3 during the treatment period (P=0.01). The median annual relative increase in coronary calcium was 25% during the untreated versus 8.8% during the treatment period (P |
| doi_str_mv | 10.1161/01.CIR.0000027567.49283.FF |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72030269</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>174455121</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-c29e70119e8def9e7d13f8d793ebbd970ab490ccb4f7db14e9b81be75f289d803</originalsourceid><addsrcrecordid>eNpdkd9r2zAQx0XZaNNu_8IwgfXNrn7YlpW3EOY2UCiM7VnI8ilTcWxHsjv63--SBgLTy91xnzvd3ZeQJaMZYyV7oCzbbH9m9Pi4LEqZ5YpXIqvrK7JgBc_TvBDqE1lgXqVScH5DbmN8xbAUsrgmN4wzVQrBF-Sw7V03Q28hGVzS-dG3aTf8heD7XTL9gWDG92Toj24yhmEXIEaPMcJ2CENvwntiwgRorOmsd96aCYFVsj7ycQQ7-TdI4M108ynzhXx2povw9WzvyO_6x6_NU_r88rjdrJ9TKwo5pZYrkJQxBVULDv2WCVe1UglomlZJappcUWub3Mm2YTmopmINyMLxSrUVFXfk_qMvjnGYIU5676OFrjM9DHPUklNBeakQXP4Hvg5z6HE2zRkvK7w5R2j1AVlcKgZwegx-j9trRvVRFU2ZRlX0RRV9UkXXNRZ_O_8wN3toL6VnGRD4fgZMxDO6YHrr44UTlcopL8Q_eBeYHA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212681162</pqid></control><display><type>article</type><title>Influence of lipid-lowering therapy on the progression of coronary artery calcification: A prospective evaluation</title><source>EZB Electronic Journals Library</source><creator>ACHENBACH, Stephan ; ROPERS, Dieter ; BICKEL, Andrea ; HABERL, Ralph ; STEINBECK, Gerhard ; MOSHAGE, Werner ; DANIEL, Werner G ; POHLE, Karsten ; LEBER, Alexander ; THILO, Christian ; KNEZ, Andreas ; MENENDEZ, Theresa ; MAEFFERT, Ralph ; KUSUS, Magda ; REGENFUS, Matthias</creator><creatorcontrib>ACHENBACH, Stephan ; ROPERS, Dieter ; BICKEL, Andrea ; HABERL, Ralph ; STEINBECK, Gerhard ; MOSHAGE, Werner ; DANIEL, Werner G ; POHLE, Karsten ; LEBER, Alexander ; THILO, Christian ; KNEZ, Andreas ; MENENDEZ, Theresa ; MAEFFERT, Ralph ; KUSUS, Magda ; REGENFUS, Matthias</creatorcontrib><description>Coronary calcification measured by fast computed tomography techniques is a surrogate marker of coronary atherosclerotic plaque burden. In a cohort study, we prospectively investigated whether lipid-lowering therapy with a cholesterol synthesis enzyme inhibitor reduces the progression of coronary calcification.
In 66 patients with coronary calcifications in electron beam tomography (EBT), LDL cholesterol >130 mg/dL, and no lipid-lowering treatment, the EBT scan was repeated after a mean interval of 14 months and treatment with cerivastatin was initiated (0.3 mg/d). After 12 months of treatment, a third EBT scan was performed. Coronary calcifications were quantified using a volumetric score. Cerivastatin therapy lowered the mean LDL cholesterol level from 164+/-30 to 107+/-21 mg/dL. The median calcified volume was 155 mm3 (range, 15 to 1849) at baseline, 201 mm3 (19 to 2486) after 14 months without treatment, and 203 mm3 (15 to 2569) after 12 months of cerivastatin treatment. The median annualized absolute increase in coronary calcium was 25 mm3 during the untreated versus 11 mm3 during the treatment period (P=0.01). The median annual relative increase in coronary calcium was 25% during the untreated versus 8.8% during the treatment period (P<0.0001). In 32 patients with an LDL cholesterol level <100 mg/dL under treatment, the median relative change was 27% during the untreated versus -3.4% during the treatment period (P=0.0001).
Treatment with the cholesterol synthesis enzyme inhibitor cerivastatin significantly reduces coronary calcium progression in patients with LDL cholesterol >130 mg/dL.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/01.CIR.0000027567.49283.FF</identifier><identifier>PMID: 12196332</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Calcinosis - blood ; Calcinosis - complications ; Calcinosis - diagnostic imaging ; Calcinosis - drug therapy ; Cholesterol, LDL - blood ; Cohort Studies ; Coronary Artery Disease - blood ; Coronary Artery Disease - complications ; Coronary Artery Disease - diagnostic imaging ; Coronary Artery Disease - drug therapy ; Disease Progression ; Female ; General and cellular metabolism. Vitamins ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hypolipidemic Agents - therapeutic use ; Lipids - blood ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Prospective Studies ; Pyridines - therapeutic use ; Tomography, X-Ray Computed ; Treatment Outcome</subject><ispartof>Circulation (New York, N.Y.), 2002-08, Vol.106 (9), p.1077-1082</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Aug 27, 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c357t-c29e70119e8def9e7d13f8d793ebbd970ab490ccb4f7db14e9b81be75f289d803</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13894025$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12196332$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ACHENBACH, Stephan</creatorcontrib><creatorcontrib>ROPERS, Dieter</creatorcontrib><creatorcontrib>BICKEL, Andrea</creatorcontrib><creatorcontrib>HABERL, Ralph</creatorcontrib><creatorcontrib>STEINBECK, Gerhard</creatorcontrib><creatorcontrib>MOSHAGE, Werner</creatorcontrib><creatorcontrib>DANIEL, Werner G</creatorcontrib><creatorcontrib>POHLE, Karsten</creatorcontrib><creatorcontrib>LEBER, Alexander</creatorcontrib><creatorcontrib>THILO, Christian</creatorcontrib><creatorcontrib>KNEZ, Andreas</creatorcontrib><creatorcontrib>MENENDEZ, Theresa</creatorcontrib><creatorcontrib>MAEFFERT, Ralph</creatorcontrib><creatorcontrib>KUSUS, Magda</creatorcontrib><creatorcontrib>REGENFUS, Matthias</creatorcontrib><title>Influence of lipid-lowering therapy on the progression of coronary artery calcification: A prospective evaluation</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>Coronary calcification measured by fast computed tomography techniques is a surrogate marker of coronary atherosclerotic plaque burden. In a cohort study, we prospectively investigated whether lipid-lowering therapy with a cholesterol synthesis enzyme inhibitor reduces the progression of coronary calcification.
In 66 patients with coronary calcifications in electron beam tomography (EBT), LDL cholesterol >130 mg/dL, and no lipid-lowering treatment, the EBT scan was repeated after a mean interval of 14 months and treatment with cerivastatin was initiated (0.3 mg/d). After 12 months of treatment, a third EBT scan was performed. Coronary calcifications were quantified using a volumetric score. Cerivastatin therapy lowered the mean LDL cholesterol level from 164+/-30 to 107+/-21 mg/dL. The median calcified volume was 155 mm3 (range, 15 to 1849) at baseline, 201 mm3 (19 to 2486) after 14 months without treatment, and 203 mm3 (15 to 2569) after 12 months of cerivastatin treatment. The median annualized absolute increase in coronary calcium was 25 mm3 during the untreated versus 11 mm3 during the treatment period (P=0.01). The median annual relative increase in coronary calcium was 25% during the untreated versus 8.8% during the treatment period (P<0.0001). In 32 patients with an LDL cholesterol level <100 mg/dL under treatment, the median relative change was 27% during the untreated versus -3.4% during the treatment period (P=0.0001).
Treatment with the cholesterol synthesis enzyme inhibitor cerivastatin significantly reduces coronary calcium progression in patients with LDL cholesterol >130 mg/dL.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Calcinosis - blood</subject><subject>Calcinosis - complications</subject><subject>Calcinosis - diagnostic imaging</subject><subject>Calcinosis - drug therapy</subject><subject>Cholesterol, LDL - blood</subject><subject>Cohort Studies</subject><subject>Coronary Artery Disease - blood</subject><subject>Coronary Artery Disease - complications</subject><subject>Coronary Artery Disease - diagnostic imaging</subject><subject>Coronary Artery Disease - drug therapy</subject><subject>Disease Progression</subject><subject>Female</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Hypolipidemic Agents - therapeutic use</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Pyridines - therapeutic use</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNpdkd9r2zAQx0XZaNNu_8IwgfXNrn7YlpW3EOY2UCiM7VnI8ilTcWxHsjv63--SBgLTy91xnzvd3ZeQJaMZYyV7oCzbbH9m9Pi4LEqZ5YpXIqvrK7JgBc_TvBDqE1lgXqVScH5DbmN8xbAUsrgmN4wzVQrBF-Sw7V03Q28hGVzS-dG3aTf8heD7XTL9gWDG92Toj24yhmEXIEaPMcJ2CENvwntiwgRorOmsd96aCYFVsj7ycQQ7-TdI4M108ynzhXx2povw9WzvyO_6x6_NU_r88rjdrJ9TKwo5pZYrkJQxBVULDv2WCVe1UglomlZJappcUWub3Mm2YTmopmINyMLxSrUVFXfk_qMvjnGYIU5676OFrjM9DHPUklNBeakQXP4Hvg5z6HE2zRkvK7w5R2j1AVlcKgZwegx-j9trRvVRFU2ZRlX0RRV9UkXXNRZ_O_8wN3toL6VnGRD4fgZMxDO6YHrr44UTlcopL8Q_eBeYHA</recordid><startdate>20020827</startdate><enddate>20020827</enddate><creator>ACHENBACH, Stephan</creator><creator>ROPERS, Dieter</creator><creator>BICKEL, Andrea</creator><creator>HABERL, Ralph</creator><creator>STEINBECK, Gerhard</creator><creator>MOSHAGE, Werner</creator><creator>DANIEL, Werner G</creator><creator>POHLE, Karsten</creator><creator>LEBER, Alexander</creator><creator>THILO, Christian</creator><creator>KNEZ, Andreas</creator><creator>MENENDEZ, Theresa</creator><creator>MAEFFERT, Ralph</creator><creator>KUSUS, Magda</creator><creator>REGENFUS, Matthias</creator><general>Lippincott Williams & Wilkins</general><general>American Heart Association, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope></search><sort><creationdate>20020827</creationdate><title>Influence of lipid-lowering therapy on the progression of coronary artery calcification: A prospective evaluation</title><author>ACHENBACH, Stephan ; ROPERS, Dieter ; BICKEL, Andrea ; HABERL, Ralph ; STEINBECK, Gerhard ; MOSHAGE, Werner ; DANIEL, Werner G ; POHLE, Karsten ; LEBER, Alexander ; THILO, Christian ; KNEZ, Andreas ; MENENDEZ, Theresa ; MAEFFERT, Ralph ; KUSUS, Magda ; REGENFUS, Matthias</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-c29e70119e8def9e7d13f8d793ebbd970ab490ccb4f7db14e9b81be75f289d803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Calcinosis - blood</topic><topic>Calcinosis - complications</topic><topic>Calcinosis - diagnostic imaging</topic><topic>Calcinosis - drug therapy</topic><topic>Cholesterol, LDL - blood</topic><topic>Cohort Studies</topic><topic>Coronary Artery Disease - blood</topic><topic>Coronary Artery Disease - complications</topic><topic>Coronary Artery Disease - diagnostic imaging</topic><topic>Coronary Artery Disease - drug therapy</topic><topic>Disease Progression</topic><topic>Female</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Hypolipidemic Agents - therapeutic use</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Pyridines - therapeutic use</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ACHENBACH, Stephan</creatorcontrib><creatorcontrib>ROPERS, Dieter</creatorcontrib><creatorcontrib>BICKEL, Andrea</creatorcontrib><creatorcontrib>HABERL, Ralph</creatorcontrib><creatorcontrib>STEINBECK, Gerhard</creatorcontrib><creatorcontrib>MOSHAGE, Werner</creatorcontrib><creatorcontrib>DANIEL, Werner G</creatorcontrib><creatorcontrib>POHLE, Karsten</creatorcontrib><creatorcontrib>LEBER, Alexander</creatorcontrib><creatorcontrib>THILO, Christian</creatorcontrib><creatorcontrib>KNEZ, Andreas</creatorcontrib><creatorcontrib>MENENDEZ, Theresa</creatorcontrib><creatorcontrib>MAEFFERT, Ralph</creatorcontrib><creatorcontrib>KUSUS, Magda</creatorcontrib><creatorcontrib>REGENFUS, Matthias</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ACHENBACH, Stephan</au><au>ROPERS, Dieter</au><au>BICKEL, Andrea</au><au>HABERL, Ralph</au><au>STEINBECK, Gerhard</au><au>MOSHAGE, Werner</au><au>DANIEL, Werner G</au><au>POHLE, Karsten</au><au>LEBER, Alexander</au><au>THILO, Christian</au><au>KNEZ, Andreas</au><au>MENENDEZ, Theresa</au><au>MAEFFERT, Ralph</au><au>KUSUS, Magda</au><au>REGENFUS, Matthias</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of lipid-lowering therapy on the progression of coronary artery calcification: A prospective evaluation</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2002-08-27</date><risdate>2002</risdate><volume>106</volume><issue>9</issue><spage>1077</spage><epage>1082</epage><pages>1077-1082</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>Coronary calcification measured by fast computed tomography techniques is a surrogate marker of coronary atherosclerotic plaque burden. In a cohort study, we prospectively investigated whether lipid-lowering therapy with a cholesterol synthesis enzyme inhibitor reduces the progression of coronary calcification.
In 66 patients with coronary calcifications in electron beam tomography (EBT), LDL cholesterol >130 mg/dL, and no lipid-lowering treatment, the EBT scan was repeated after a mean interval of 14 months and treatment with cerivastatin was initiated (0.3 mg/d). After 12 months of treatment, a third EBT scan was performed. Coronary calcifications were quantified using a volumetric score. Cerivastatin therapy lowered the mean LDL cholesterol level from 164+/-30 to 107+/-21 mg/dL. The median calcified volume was 155 mm3 (range, 15 to 1849) at baseline, 201 mm3 (19 to 2486) after 14 months without treatment, and 203 mm3 (15 to 2569) after 12 months of cerivastatin treatment. The median annualized absolute increase in coronary calcium was 25 mm3 during the untreated versus 11 mm3 during the treatment period (P=0.01). The median annual relative increase in coronary calcium was 25% during the untreated versus 8.8% during the treatment period (P<0.0001). In 32 patients with an LDL cholesterol level <100 mg/dL under treatment, the median relative change was 27% during the untreated versus -3.4% during the treatment period (P=0.0001).
Treatment with the cholesterol synthesis enzyme inhibitor cerivastatin significantly reduces coronary calcium progression in patients with LDL cholesterol >130 mg/dL.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>12196332</pmid><doi>10.1161/01.CIR.0000027567.49283.FF</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-7322 |
| ispartof | Circulation (New York, N.Y.), 2002-08, Vol.106 (9), p.1077-1082 |
| issn | 0009-7322 1524-4539 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72030269 |
| source | EZB Electronic Journals Library |
| subjects | Adult Aged Biological and medical sciences Calcinosis - blood Calcinosis - complications Calcinosis - diagnostic imaging Calcinosis - drug therapy Cholesterol, LDL - blood Cohort Studies Coronary Artery Disease - blood Coronary Artery Disease - complications Coronary Artery Disease - diagnostic imaging Coronary Artery Disease - drug therapy Disease Progression Female General and cellular metabolism. Vitamins Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypolipidemic Agents - therapeutic use Lipids - blood Male Medical sciences Middle Aged Pharmacology. Drug treatments Prospective Studies Pyridines - therapeutic use Tomography, X-Ray Computed Treatment Outcome |
| title | Influence of lipid-lowering therapy on the progression of coronary artery calcification: A prospective evaluation |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T15%3A49%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20lipid-lowering%20therapy%20on%20the%20progression%20of%20coronary%20artery%20calcification:%20A%20prospective%20evaluation&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=ACHENBACH,%20Stephan&rft.date=2002-08-27&rft.volume=106&rft.issue=9&rft.spage=1077&rft.epage=1082&rft.pages=1077-1082&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/01.CIR.0000027567.49283.FF&rft_dat=%3Cproquest_cross%3E174455121%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c357t-c29e70119e8def9e7d13f8d793ebbd970ab490ccb4f7db14e9b81be75f289d803%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=212681162&rft_id=info:pmid/12196332&rfr_iscdi=true |